10 completed, 1 terminated. 5 Phase 3, 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow telcagepant: new trials by email Literature Review of telcagepant trials Research Report on telcagepant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065) Telcagepant, Placebo - Migraine | Phase 2 / Phase 3 | Completed | Merck Sharp & Dohme LLC | 4548 | 2010-06-01 | 2018-10-23 |
| Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067) telcagepant, [11C]MK-4232 - Migraine | Phase 1 | Completed | Merck Sharp & Dohme LLC | 10 | 2010-01-14 | 2019-04-02 |
| A Study to Test the Safety and Effectiveness of MK-0974 (Telcagepant) Co-administered With Ibuprofen or Acetaminophen in Patients With Migraines With or Without Aura (MK-0974-046) placebo, ibuprofen, acetominophen - Migraine | Phase 2 | Completed | Merck Sharp & Dohme LLC | 683 | 2008-12-03 | 2018-10-22 |
| MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) Telcagepant 140 mg, Telcagepant 280 mg, 140 mg telcagepant placebo - Migraine | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 660 | 2008-11-12 | 2018-10-18 |
| Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) Telcagepant 140 mg, Talcagepant 280 mg, Placebo - Migraines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1935 | 2008-08-14 | 2018-10-18 |
| Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) Telcagepant, Acetaminophen/Paracetamol, Placebo to Telcagepant - Migraine Disorders, Heart Disease | Phase 3 | Completed | Merck Sharp & Dohme LLC | 165 | 2008-03-17 | 2018-10-19 |
| Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042) MK0974 tablet, Comparator: MK0974 liquid filled capsule - Migraine | Phase 1 | Completed | Merck Sharp & Dohme LLC | 50 | 2008-03-01 | 2015-07-07 |
| A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014) telcagepant, Placebo to telcagepant - Angina Pectoris, Coronary Heart Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 64 | 2008-02-12 | 2018-10-18 |
| Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016) MK0974 50 mg, MK0974 150 mg, MK0974 300 mg - Migraine | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1703 | 2007-03-01 | 2015-07-03 |
| Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012) Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets - Migraine | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1068 | 2007-02-21 | 2018-10-17 |
| A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004) Comparator: Placebo, MK0974, Rizatriptan - Migraine | Phase 2 | Completed | Merck Sharp & Dohme LLC | 420 | 2005-11-01 | 2015-11-02 |
Migraine Disorders (10) · Angina Pectoris (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Heart Diseases (1) · Ischemic Attack, Transient (1) · Peripheral Vascular Diseases (1) · Stroke (1) · Vascular Diseases (1)
PMID 19770473, PMID 20974601, PMID 21070230, PMID 21457238, PMID 22221076, PMID 22278333, PMID 23975906, PMID 25107879, PMID 25926620